Richard Buka: Exploring the COBRRA Trial in the Latest Episode of Don’t Just Read the Abstract
Richard Buka, Academic Clinical Lecturer at University of Birmingham, shared a post on LinkedIn about a recent article by Lana A. Castellucci et al. published in NEJM:
“Pip Nicolson and I have just released the latest episode of Don’t Just Read the Abstract.
In it, we discuss the COBRRA trial: Apixaban vs Rivaroxaban for Acute Venous Thromboembolism (Castellucci et al. 2026, NEJM).
Check it out – and let us know if we missed something important!”
Title: Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Authors: Lana A. Castellucci, Vivien M. Chen, Michael J. Kovacs, Alejandro Lazo-Langner, Peter Greenstreet, Susan Kahn, Benoit Côté, Sam Schulman, Kerstin de Wit, James Douketis, Deepa Suryanarayan, Tony Wan, Erik Yeo, Genevieve Le Templier, Huyen A. Tran, Abbey Willcox, Helen J. Crowther, Ritam Prasad, Sudeep Shivakumar, Etimbuk Umana, Fionnuala Ni Ainle, Tobias Tritschler, Stefano Barco, Jean-Philippe Galanaud, Marc Blondon, Lisa Baumann Kreuziger, Susan Solymoss, Clive Kearon, Erin Thomas, Tim Ramsay, Gregoire Le Gal, Marc Rodger
Read the Full Article on NEJM
Stay updated with Hemostasis Today.
-
Sep 22, 2026, 19:02Blocking Histone-Induced Platelet-Erythrocyte Interactions With Polyanions – Platelets Journal
-
Sep 22, 2026, 18:49Abdul Rahman Hamad: Early Action for Better Outcomes in Deep Vein Thrombosis
-
Sep 22, 2026, 18:37Carmine Siniscalchi: Age-Adjusted D-Dimer Cutoffs in DVT Diagnosis
-
Sep 22, 2026, 18:37Stefano Romeo: The Cardiovascular Patient Journey is Still Full of Gaps
-
Sep 22, 2026, 18:11Bharath Kumar V.։ Advancing Safer Anticoagulation for Cancer-Associated Thrombosis
-
Sep 22, 2026, 18:10Fatima Zahra: ASH Released New Guidelines on the Diagnosis of Iron Deficiency
-
Sep 22, 2026, 17:49Nirav Dhanesha: Targeting FXI for Safer Anticoagulation
-
Sep 22, 2026, 17:17Eric Lambert: Intravascular Imaging and the Future of Precision PCI
-
Sep 22, 2026, 16:45Claudiu Stoicescu: Are We Starting Cardiovascular Risk Assessment Too Late?